<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34093">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02662764</url>
  </required_header>
  <id_info>
    <org_study_id>IAP312</org_study_id>
    <nct_id>NCT02662764</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg</brief_title>
  <official_title>A Multicenter, Open-Label Trial to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AcelRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AcelRx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who meet all inclusion and exclusion criteria at screening and following surgery
      will receive the Zalviso System™ and evaluate its usability and functionality for up to 72
      hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 315 adult postoperative in-patients who are expected to require opioid
      analgesia for at least 24 hours, and up to 72 hours, after surgery will be enrolled.
      Patients will use the Zalviso™ (sufentanil sublingual tablet system) 15 mcg in order to
      self-administer a tablet of study drug as needed for pain. The System will be evaluated for
      usability and functionality.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device Functionality: Proportion of patients who experience at least one system-generated error</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Proportion of patients who experience at least one system-generated error based on the Controller data while using the Zalviso System</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device Usability: Proportion of patients with misplaced tablets</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Proportion of patients with misplaced tablets</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">315</enrollment>
  <condition>Moderate-to-severe Acute Pain</condition>
  <arm_group>
    <arm_group_label>Zalviso™ 15 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zalviso™(sufentanil sublingual tablet system) 15 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zalviso™ 15 mcg</intervention_name>
    <description>Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for up to 72 hours</description>
    <arm_group_label>Zalviso™ 15 mcg</arm_group_label>
    <other_name>Zalviso™ (sufentanil sublingual tablet system) 15 mcg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients who are 18 years of age or older.

          2. Patients who are scheduled to undergo surgery under general or spinal anesthesia that
             does not include intrathecal opioids during the operation.

          3. Patients classified as American Society of Anesthesiologists (ASA) class I - III
             (Appendix I).

          4. Female patients of childbearing potential must be using an effective method of birth
             control at the time of screening visit and for 30 days following the end of the study
             period. Acceptable methods of birth control include oral or transdermal
             contraceptives, condom, spermicidal foam, intrauterine device (IUD), progestin
             implant or injection, abstinence, vaginal ring, or sterilization of partner. The
             reason for non-child bearing potential, such as bilateral tubal ligation, bilateral
             oophorectomy, hysterectomy, or postmenopausal for &gt; 1 year, must be specified.
             Patients using hormonal forms of contraception must also be willing to use a barrier
             method of contraception from screening through 30 days following the study period.

          5. Post-surgical patients who have been admitted to the PACU, and are expected to have
             acute pain requiring opioids for 24 - 72 hours after surgery.

        Exclusion Criteria:

          1. Patients who have taken an opioid for more than 30 consecutive days, at a daily dose
             of 15 mg or more of morphine (or equivalent), within the past 3 months prior to
             surgery (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg
             hydrocodone per tablet).

          2. Patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken
             MAOIs within 14 days of the first dose of study drug.

          3. Patients with current sleep apnea that has been documented by a sleep laboratory
             study or are on home continuous positive airway pressure (CPAP).

          4. Patients with an allergy or hypersensitivity to opioids.

          5. Patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken
             MAOIs within 14 days of the first dose of study drug.

          6. Patients with current sleep apnea that has been documented by a sleep laboratory
             study or are on home continuous positive airway pressure (CPAP).

          7. Patients who are receiving oxygen therapy at the time of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Palmer, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AcelRx Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrianne Neighbors</last_name>
    <phone>1 919 786 8914</phone>
    <email>NeighborsAdrianne@prahs.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Llanes</last_name>
    <phone>913-410-2855</phone>
    <email>LlanesJennifer@prahs.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eliza Coffee Memorial Hospital</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <zip>35630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Cosby</last_name>
      <phone>256-768-8021</phone>
      <email>mcosby@chgroup.com</email>
    </contact>
    <investigator>
      <last_name>David Boyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shoals Medical Trials</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Puckett</last_name>
      <phone>256-386-4001</phone>
      <email>puckchristy@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Timothy Melson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Freeman</last_name>
      <phone>602-778-3018</phone>
      <email>mfreeman@azresearchcenter.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Gimbel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gulfcoast Research Associates</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Chaundy</last_name>
      <phone>727-584-6368</phone>
      <email>shannonchaundy@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Edward Stolarski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>G&amp;G Research</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Gervasio</last_name>
      <phone>772-469-2828</phone>
      <email>ggresearch20@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Edward Murphy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orthopedic Center of Vero Beach</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Gervasio</last_name>
      <phone>772-469-2828</phone>
      <email>ggresearch20@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Richard Steinfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Martinez</last_name>
      <phone>561-460-4395</phone>
      <email>smartinez@atlanticclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Keith Aqua, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Center for Clinical Trials</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30333</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Maslanka, PA, MPH</last_name>
      <phone>404-216-7099</phone>
      <email>marc@secctweb.com</email>
    </contact>
    <investigator>
      <last_name>Maurice Jove, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Surgical Clinical Associates</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Griffith, BSN</last_name>
      <phone>601-506-8298</phone>
      <email>suzanne.researchpartners@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Scott Berry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westside Surgical Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Lindley</last_name>
      <phone>832-567-2273</phone>
      <email>pam@minkowitzmd.com</email>
    </contact>
    <investigator>
      <last_name>Harold Minkowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hermann Drive Surgical Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Howard</last_name>
      <phone>281-770-5752</phone>
      <email>lauren@minkowitzmd.com</email>
    </contact>
    <investigator>
      <last_name>David Leiman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol Minoughan, B.S.</last_name>
      <phone>801-261-2000</phone>
      <phone_ext>317</phone_ext>
      <email>cminoughan@jeanbrownresearch.com</email>
    </contact>
    <investigator>
      <last_name>Derek Muse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 27, 2017</lastchanged_date>
  <firstreceived_date>January 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
